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ion, not just an academic discussion, because the role of
rs8099917 has been clariﬁed and deepened in several studies
and we think it should be included as best SVR predictor in the
genotype 1 [2–4]. The major impact of rs12979860 has been doc-
umented on the early response [5], while rs8099917 in a recent
meta-analysis evidenced the best predictive effect on the SVR
(OR = 5.171 vs. 4.473) [6]. In fact, the effect of this SNP explains
the higher rate of relapse in patients who achieved both RVR
and ETR with the CC rs12979860 genotype, but with the presence
of a G allele for the rs8099917 SNP [5]. Conversely, patients with-
out the CC genotype for rs12979860 retain good probability to
reach SVR if they have the TT genotype for rs8099917; this issue
could underlie the high rate of SVR in non-CC patients reported
by Andriulli et al. [1] and according with the TT prevalence in
the Italian population. Therefore, we consider it essential to get
both rs12979860 and rs8099917 SNPs as predictors on SVR
and, in more detail, we could select the patients with CC/TT or
CT/TT, but not with CC/TG or CC/GG genotype, for dual therapy.
Another not considered issue in the analysis is the role of ther-
apeutic drug monitoring (TDM) of ribavirin (RBV) as useful early
on treatment predictor of response and toxicity. Ribavirin shows
a wide inter-individual variability in plasma concentrations
(25–30%) and weight-based dose results often inadequate with-
out TDM support [3,4,7]. Interestingly, RBV concentrations are
related both with EVR and SVR [3,4,8,9] or treatment failure in
HCV-1 infected patients, according to different plasma concentra-
tions at different time-points. The optimal therapeutic range of
RBV could maximize the SVR achievement and it should be com-
prised between 2–2.5 mg/L (at week 4 of therapy), according to
the majority of the reviewed studies [10].
In conclusion, we suggest that both IL28B SNPs should be con-
sidered in order to reﬁne the selection of candidate patients for
dual therapy and then the TDM of RBV should be used to improve
the on-treatment management.
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itor:
We thank Dr. Boglione and colleagues [1] for their comments on
our recently published paper on the identiﬁcation of naïve HCV-1
patients with chronic hepatitis who may beneﬁt from dual ther-
apy with peg-interferon (PegIFN) and ribavirin (RBV) [2]. To date,
several single nucleotide polymorphisms (SNPs) in the genes
encoding for IFN-k1 (IL29), IFN-k2 (IL28A), IFN-k3 (IL28B), and
IFN-k4 (IFNL4) have been established as predictors of treatmentJournal of Hepatology 20
 under CC BY-NC-ND license.response to PegIFN/RBV [3,4]. Among the identiﬁed SNPs,
rs8099917, rs12979860, and the newly ss469415590 polymor-
phisms have been extensively investigated. Although with con-
ﬂicting results, the question about which of the aforementioned
SNPs, alone or in combination, is (or are) the best baseline mar-
ker(s) of SVR in patients HCV1 is still debated.
Dr. Boglione et al. argue that the contemporary evaluation of
the two SNPs of the IL28B locus may portend greater information14 vol. 61 j 169–182 179
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Table 1. Genotypes distribution of rs12979860 and rs8099917 SNPs in IL28B locus and Sustained Virological Response (SVR).
rs12979860 
CC SVR (%) CT SVR (%) TT SVR (%) 
rs8099917 
GG 0 0 (0) 3 0 (0) 33 7 (21)
TG 15 7 (47) 208 62 (30) 42 10 (24)
TT 104 74 (71) 118 39 (33) 16 5 (16)
Letters to the Editoron the actual outcome of therapy, as the rs12979860 could better
predict RVR, whereas the rs8099917 would be more informative
for SVR. We addressed this point in a subsequent manuscript
where 539 patients of the entire cohort, for whom blood samples
were available, were genotyped for the two SNPs [5]. In our
patients the rs12979860 resulted to have a greater impact of
the rs8099917 for either RVR (OR = 4.69, 95% CI 3.00–7.34 vs.
OR = 3.01, 95% CI 1.97–4.59) and SVR (OR = 5.15, 95% CI 3.32–
7.98 vs. OR = 2.46, 95% CI 1.72–3.51). Moreover, we entered the
two SNPs together with the new ss469415590 dinucleotide vari-
ant (located in IFNL4 gene) into a multiple logistic model and the
hit SNP appeared to be the rs12979860CC genotype, as it was the
only one to retain an independent prediction power for SVR
(OR = 3.39; 95% CI 1.61–7.13). The discrepancy between our data
and the referenced results by Stättermayer et al. [6] could be
explained by differences in the HCV genotypes between patients
enrolled into the two studies: while our data refer to only
patients with HCV-1, the Stättermayer cohort of patients was a
mix population of patients infected by all HCV genotypes.
A further point raised by Dr. Boglione concerns the capability
of predicting SVR in patients with the rs12979860 non-CC type
by determining the TT genotype of the rs8099917. In the accom-
panying Table 1, we stratiﬁed our patients by both genotypes: of
the 420 individuals with non-CC type, SVR rates were docu-
mented in 33% (44/134), 29% (72/250), and 19% (7/36) of subjects
with the rs8099917 subtypes TT, TG or GG, respectively.
While we may agree with our colleagues that monitoring of
ribavirin levels during therapy could also impact positively on
the outcome of therapy, we have not considered this point in
our work.
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manuscript.Virtual portal pressure from anatomic CT angiography
To the Editor:
We read with great interest the paper ‘‘Accurate computed
tomography-based portal pressure assessment in patients with
hepatocellular carcinoma’’, which proposed a novel CT-based
model in the prediction of hepatic venous pressure gradient
(HVPG) [1]. By combining liver/spleen volume ratio and the pres-
ence of peri-hepatic ascites, this non-invasive model had a very
good accuracy in predicting HVPG >10 mmHg [1]. Although HVPG
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